Clostridioides Difficile Infection
3
Pipeline Programs
3
Companies
4
Clinical Trials
1 recruiting
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
1
1
1
0
Early DiscoveryClinical DevelopmentMarket
Competitive Landscape
3 companies ranked by most advanced pipeline stage
Seres TherapeuticsCAMBRIDGE, MA
2 programs1
SER-109Phase 31 trial
SER-109N/A1 trial
Active Trials
NCT02437500Approved For Marketing
Trial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
2027
Seres TherapeuticsSER-109
Lumen BioscienceLMN-201
CrestoneCRS3123
Clinical Trials (4)
Total enrollment: 375 patients across 4 trials
ECOSPOR IV: An Open-Label Study Evaluating SER-109 in Recurrent Clostridioides Difficile Infection
Start: Oct 2017Est. completion: Apr 2022
Phase 3Completed
LMN-201 for Prevention of C. Difficile Infection Recurrence
Start: Aug 2024Est. completion: Dec 2027375 patients
Phase 2/3Recruiting
Evaluation of CRS3123 vs. Oral Vancomycin in Adult Patients With Clostridioides Difficile Infection
Start: Jan 2021Est. completion: Apr 2024
Phase 2Completed
Expanded Access Program of SER-109 in the Treatment of Adults With Recurrent Clostridioides Difficile Infection (RCDI)
N/AApproved For Marketing
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
1 late-stage (Phase 3) programs — potential near-term approvals
1 actively recruiting trials targeting 375 patients
3 companies competing in this space